HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS

The aim of the work was to determine the antidiabetic effect of a sitagliptin and aminoguanidine combination in rats with experimental diabetes mellitus.

Materials and methods. The study was carried out on male Wistar rats and C57BL/KsJ-db/db mice. According to the models used, it was divided into 4 series, in which alloxan, steroid-induced (dexamethasone) and streptozotocin-nicotinamide-induced diabetes mellitus (DM) were formed, respectively, in rats, and in the 4 series, obese C57BL/KsJ-db/db mice were used. In the 1 and 2 series, the treatment was started prophylactically – 3 h after the alloxan administration and simultaneously with the dexamethasone administration, in the 3rd and 4th series, the treatment was carried out after the pathology had developed – 7 days after the streptozotocin with nicotinamide administration, and in the obese mice – immediately after their distribution according to the groups. The treatment was carried out with sitagliptin (10 mg/kg), aminoguanidine (25 mg/kg), or a combination thereof. The treatment was continued till the end of the experiment, which was completed with an oral glucose tolerance test (OGTT) after 4 h of fasting. The obtained data were subjected to statistical processing.

Results. In the course of the experiments, it was found out that the prophylactic administration of a sitagliptin and aminoguanidine combination, unlike each of the components, prevented the development of alloxan DM. More effectively than the administration of sitagliptin alone, it reduced the severity of steroid-induced DM, which was expressed in a significantly lower level of fasting glycemia (after 4 h of fasting) and postprandial glycemia (during OGTT). Under the conditions of streptozotocin-nicotinamide-induced DM, the studied combination slowed down the progression of the pathology, and in the obese mice, the course therapeutic administration of sitagliptin and its combination reduced the severity of carbohydrate metabolism disorders (fasting glycemia) and increased the rate of glucose utilization.

Conclusion. As an iNOS blocker, aminoguanidine enhances the antidiabetic effect of sitagliptin, preventing the development of alloxan diabetes and reducing the severity of steroid-induced DM when administered prophylactically. When administered therapeutically, it reduces the severity of streptozotocin-nicotinamide-induced DM in rats and type 2 DM in mice with a predisposition to obesity.

1. Dedov II, Shestakova MV, Mayorov AYu, Mokrysheva NG, Vikulova OK, Galstyan GR, Kuraeva TL, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Sukhareva OY, Tokmakova AY, Shamkhalova MS, Jarek-Martynova IR, Artemova EV, Beshlieva DD, Bondarenko ON, Volevodz NN, Gomova IS, Grigoryan OR, Dzhemilova ZN, Esayan RM, Ibragimova LI, Kalashnikov VY, Kononenko IV, Laptev DN, Lipatov DV, Melnikova OG, Mikhina MS, Michurova MS, Motovilin OG, Nikonova TV, Rozhivanov RV, Sklyanik IA, Shestakova EA. Standards of specialized diabetes care Edited by Dedov II, Shestakova MV, Mayorov AYu. 10th edition. Diabetes mellitus. 2021;24(1S):1–148. DOI:10.14341/DM12802. Russian

2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. DOI:10.1016/j.diabres.2021.109119

3. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204–21. DOI:10.14341/DM12759. Russian

4. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. DOI:10.1016/j.eprac.2022.08.002

5. Trigolosova IV. Steroid-induced diabetes mellitus. RMZH. 2016;24(1):54–6. Russian

6. Wallace MD, Metzger NL. Optimizing the Treatment of Steroid-Induced Hyperglycemia. Ann Pharmacother. 2018 Jan;52(1):86–90. DOI:10.1177/1060028017728297

7. Shah P, Kalra S, Yadav Y, Deka N, Lathia T, Jacob JJ, Kota SK, Bhattacharya S, Gadve SS, Subramanium KAV, George J, Iyer V, Chandratreya S, Aggrawal PK, Singh SK, Joshi A, Selvan C, Priya G, Dhingra A, Das S. Management of Glucocorticoid-Induced Hyperglycemia. Diabetes Metab Syndr Obes. 2022 May 23;15:1577–88. DOI:10.2147/DMSO.S330253

8. Strongin LG, Nekrasova TA, Belikina DV, Korneva KG, Petrov AV. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56–65. DOI:10.14341/probl12840. Russian

9. Sidorov AV. Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review. Effective pharmacotherapy. 2020;16(25):24–49. DOI:10.33978/2307-3586-2020-16-25-24-48

10. Tyurenkov IN, Bakulin DA, Kurkin DV, Volotova EV. Neuroprotective properties of incretin mimetics in brain ischemia and neurodegenerative diseases. Problems of Endocrinology. 2017;63(1):58–67. DOI:10.14341/probl201763158-67

11. Kurkin DV, Abrosimova EE, Bakulin DA, Kovalev NS, Dubrovina MA, Borisov AV, Strygin AV, Morkovin EI, Tyurenkov IN. Activity modulation of various nitric oxide syntases as an approach to endothelial dysfunction therapy. Pharmacy & Pharmacology. 2022;10(2):130–53. DOI:10.19163/2307-9266-2022-10-2-130-153

12. Corbett JA, McDaniel ML. The Use of Aminoguanidine, a Selective iNOS Inhibitor, to Evaluate the Role of Nitric Oxide in the Development of Autoimmune Diabetes. Methods. 1996 Aug;10(1):21–30. DOI:10.1006/meth.1996.0074

13. Panagiotopoulos S, O’Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis. 1998 Jan;136(1):125–31. DOI:10.1016/s0021-9150(97)00192-5

14. Arif B, Arif Z, Ahmad J, Perveen K, Bukhari NA, Ashraf JM, Moinuddin, Alam K. Attenuation of hyperglycemia and amadori products by aminoguanidine in alloxan-diabetic rabbits occurs via enhancement in antioxidant defenses and control of stress. PLoS One. 2022 Jan 5;17(1):e0262233. DOI: 10.1371/journal.pone.0262233

15. Oleson BJ, Corbett JA. Dual Role of Nitric Oxide in Regulating the Response of β Cells to DNA Damage. Antioxid Redox Signal. 2018 Nov 10;29(14):1432–45. DOI: 10.1089/ars.2017.7351

16. Gheibi S, Ghasemi A. Insulin secretion: The nitric oxide controversy. EXCLI J. 2020 Sep 8;19:1227–45. DOI:10.17179/excli2020-2711

17. Anavi S, Tirosh O. iNOS as a metabolic enzyme under stress conditions. Free Radic Biol Med. 2020 Jan;146:16–35. DOI: 10.1016/j.freeradbiomed.2019.10.411

18. Soskić SS, Dobutović BD, Sudar EM, Obradović MM, Nikolić DM, Djordjevic JD, Radak DJ, Mikhailidis DP, Isenović ER. Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. Open Cardiovasc Med J. 2011;5:153–63. DOI:10.2174/1874192401105010153

19. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys. 2003 Nov 1;419(1):31–40. DOI: 10.1016/j.abb.2003.08.013

20. Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, Yamamoto T, Matsuhisa M, Shimomura I. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011 Jan 7;404(1):534–40. DOI:10.1016/j.bbrc.2010.12.021

21. Kovaleva MA, Makarova MN, Makarov VG. Review Of Genetically Modified Lines Of The Laboratory Animals Used As Model Metabolic Syndrome And Diabetes Mellitus Models. Laboratory Animals for Science. 2018;1:22–31. DOI:10.29296/2618723X-2018-01-03

22. Katsuda Y, Ohta T, Shinohara M, Bin T, Yamada T. Diabetic mouse models. Open J Anim Sci. 2013;3(4):334-42. DOI:10.4236/ojas.2013.34050

23. Tyurenkov IN, Kurkin DV, Bakulin DA, Volotova EV, Morkovin EI, Chafeev MA, Karapetian RN. Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. Front Endocrinol (Lausanne). 2018 Sep 19;9:543. DOI:10.3389/fendo.2018.00543

24. Sheriff OL, Olayemi O, Taofeeq AO, Riskat KE, Ojochebo DE, Ibukunoluwa AO. A new model for alloxan-induced diabetes mellitus in rats. J Bangladesh Society of Physiologist. 2020;14(2):56–62. DOI:10.3329/jbsp.v14i2.44785

25. Rais N, Ved A, Ahmad R, Parveen K, Gautam GK, Bari DG, Shukla KS, Gaur R, Singh AP. Model of Streptozotocin-nicotinamide Induced Type 2 Diabetes: a Comparative Review. Curr Diabetes Rev. 2022;18(8):e171121198001. DOI: 10.2174/1573399818666211117123358

26. Okamoto T, Shimada T, Matsumura C, Minoshima H, Ban T, Itotani M, Shinohara T, Fujita S, Matsuda S, Sato S, Kanemoto N. New Approach to Drug Discovery of a Safe Mitochondrial Uncoupler: OPC-163493. ACS Omega. 2021 Jun 21;6(26):16980–8. DOI: 10.1021/acsomega.1c01993

27. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017 Feb;77(2):209–24. DOI: 10.1007/s40265-016-0686-9